Helmy Eltoukhy, CEO of Guardant Health, joins South Park Commons Partner Mark Jacobstein to discuss his journey from electrical engineering to building one of the leading companies in cancer diagnostics.

They talk about Guardant’s path from liquid biopsy to early cancer detection, the difficult realities of building a diagnostics company, and why business model innovation can matter just as much as technical breakthroughs.

Helmy also explains how AI is helping Guardant make better use of its growing dataset and why he believes the same blood test infrastructure could eventually be used to detect hundreds or even thousands of diseases.

Helmy Eltoukhy: https://www.linkedin.com/in/helmy-eltoukhy-b011855/
Mark Jacobstein: https://www.linkedin.com/in/markjacobstein
South Park Commons: https://www.linkedin.com/company/southparkcommons/

Apply to SPC: https://www.southparkcommons.com/apply

Chapters:

(00:00:43) - From Electrical Engineering to Biology and Entrepreneurship

(00:08:10) - From Building Sequencing Technology to Solving Healthcare Problems

(00:12:51) - Guardant Health's Long-Term Bet on Early Cancer Detection

(00:15:31) - Early Mistakes, Pivots, and Difficult Business Decisions

(00:18:15) - Why Building a Diagnostics Company Is So Difficult

(00:21:15) - Why Business Model Innovation Matters as Much as Technology

(00:26:15) - How AI Is Unlocking Guardant's Massive Cancer Dataset

(00:30:05) - From Early Cancer Detection to the “Everything Test”

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health

Minus One

The Blood Test That Could Detect Thousands of Diseases | Helmy Eltoukhy, Guardant Health